Effect of hyperlipidemia on prognosis of the patients with hepatitis B related hepatocellular carcinoma
10.16139/j.1007-9610.2024.02.09
- VernacularTitle:高脂血症对乙肝相关肝细胞癌病人预后的影响
- Author:
Qingjie SONG
1
;
Juanjuan TANG
;
Jianquan ZHAO
;
Hui SONG
;
Jun YANG
Author Information
1. 启东市人民医院 启东肝癌防治研究所 南通大学附属启东医院 普外科,江苏 启东 226200
- Keywords:
Hyperlipidemia;
Hepatocellular carcinoma;
Hepatitis B related;
Lipid-lowering treatment;
Statin;
Prognosis
- From:
Journal of Surgery Concepts & Practice
2024;29(2):143-147
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the effect of hyperlipidemia and lipid-lowering therapy on the prognosis of postoperative patients with hepatitis B related hepatocellular carcinoma.Methods The clinical data of the patients with hepatitis B related hepatocellular carcinoma who were operated in our hospital from January 2012 to January 2021 were retrospectively collected.The effect of blood lipid level and related lipid-lowering therapy on the prognosis of postoperative patients with hepatitis B related hepatocellular carcinoma was analyzed.Results Among 166 patients with hepatitis B related hepatocellular carcinoma,there were 63 cases had hyperlipidemia,of which 33 cases were treated by statins.The median postoperative disease free survival time in the hyperlipidemia group was significantly lower than that in the normal blood lipid group(24.8 months vs.38.5 months,P＜0.05),and the median overall survival time in the hyperlipidemia group was also significantly lower than that in the normal blood lipid group(30.1 months vs.44.5 months,P＜0.05).There was no statistically significant difference in prognosis between the patients with hyperlipidemia who used statins or not.The median disease free survival time was 23.4 months vs.26.3 months,and the median overall survival time was 29.7 months vs.30.3 months.Conclusions Hyperlipidemia is a risk factor for disease free survival and overall survival after surgery in the patients with hepatitis B related hepatocellular carcinoma.The use of statins alone in hyperlipidemia patients cannot reduce the risk of recurrence and prolong survival time.
